SCHEMBL13137112

SCHEMBL13137112

c1ccc2c(c1)CC(NCc1ccc(-c3ncnc4[nH]cnc34)cc1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 3/20 0.44
▸ AKT2 P31751 2/20 0.39
▸ PRKACA P17612 1/20 0.39
▸ PRKACG P22612 1/20 0.39
▸ PRKACB P22694 1/20 0.39
▸ HDAC1 Q13547 2/20 0.39
▸ FYN P06241 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PRMT5 O14744 1/20 0.37
▸ BTK Q06187 1/20 0.36
▸ NR1I3 Q14994 1/20 0.36
▸ AXL P30530 1/20 0.35
▸ DRD2 P14416 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRD1 P41143 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3928244 0.76 AKT2 (0.64) AKT2PRKACAPRKACGPRKACBBTK
SCHEMBL13137237 0.74 PRMT5 (0.42) GRIN2BHDAC1FYNMEN1RAB9A
SCHEMBL13137111 0.74 PRMT5 (0.42) GRIN2BHDAC1FYNMEN1RAB9A
SCHEMBL13137057 0.74 GRIN2B (0.41) GRIN2BHDAC1FYNMEN1RAB9A
Hydrochloric Acid SCHEMBL3049410 0.73 PRMT5 (0.41) GRIN2BHDAC1FYNMEN1RAB9A
Hydrochloric Acid SCHEMBL3034456 0.73 PRMT5 (0.41) GRIN2BHDAC1FYNMEN1RAB9A
Hydrochloric Acid SCHEMBL3051501 0.73 GRIN2B (0.41) GRIN2BHDAC1FYNMEN1RAB9A
SCHEMBL2938674 0.73 JAK2 (0.54) AKT2PRKACAPRKACGPRKACB
SCHEMBL6643407 0.73 GBA1 (0.39) —
SCHEMBL3044397 0.73 HDAC1 (0.46) GRIN2BHDAC1FYNMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 — — US disclosed
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 — — US disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 GRIN2B 148/4885AKT2 3347/4885PRKACA 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback